Quad Screen

Test Code

CPT Codes
82105, 82677, 84702, 86336

AFP, unconjugated Estriol, hCG, Dimeric Inhibin A and Maternal Risk Interpretation

Preferred Specimen
3 mL serum collected in a red-top tube (no gel), or serum separator tube (SST®)

Minimum Volume
1 mL

For assistance with any changes to this report or recalculations, please call 1-800-336-3718 ext. 65905.

For assistance with interpretation of these results, please contact your local Quest Diagnostics Genetic Counselor or call 1-866-GENE-INFO.

Transport Container

Plastic screw-cap vial

Transport Temperature
Room temperature

Specimen Stability
Room temperature: 7 days

Refrigerated: 7 days

Frozen: 28 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Gross lipemia

Immunoassay (IA)

**This test is not available for New York State patient testing, for New York State patient testing, use test code 16333.**
This is a screening test, not a diagnostic test.
The FDA has not approved any testing reagent system for use in the estimation during pregnancy of the risk of chromosomal abnormalities.

Quad Screen results consistent with an increased risk of trisomy should be confirmed with amniotic fluid specimen. Results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.

Reference Range
See Laboratory Report

Clinical Significance
Maternal serum Quad Screen is used for prenatal screening of Down syndrome (Trisomy 21), Trisomy 18 (Edwards syndrome), and open neural tube defects (ONTD). This profile includes alpha-fetaprotein (AFP), unconjugated estriol (µE3), human chorionic gonadotropin (hCG), and inhibin A. Establishing risk for fetal Down syndrome, using the quad screen achieves a 70-75% detection rate with a 5% false positive rate. Screening for Trisomy 18 detects 60% of affected fetuses with a 0.2% false positive rate. MSAFP screening detects 88% of anencephaly and 79% of open spina bifida with a 3% false positive rate. Normal results do not ensure birth of a normal infant. In addition, 2-3% of newborns have some type of physical or mental defect, many of which may be undetectable with current prenatal diagnostic procedures.

Performed By
Quest Diagnostics Nichols Institute

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.